SCHEMBL17200280

SCHEMBL17200280

COc1ccc(Cn2c(=O)c(C)c(-c3ccc(O)cc3)n(C)c2=O)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.48
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 3/20 0.42
TSHR P16473 2/20 0.42
HTT P42858 2/20 0.42
FEN1 P39748 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MAPK10 P53779 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
KDM4E B2RXH2 2/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18428422 0.88 ESR1 (0.47) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL18428426 0.87 ESR1 (0.49) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL18428428 0.87 ESR1 (0.42) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL15666946 0.86 LMNA (0.42) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL18428421 0.84 PDE7A (0.47) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL16335142 0.82 LMNA (0.39) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL18428425 0.79 HSP90AA1 (0.43) ESR1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL15666947 0.79 MAPK10 (0.47) LMNASMN1; SMN2KMT2AALDH1A1TSHR
SCHEMBL18428423 0.74 PDE7A (0.46) ESR1LMNASMN1; SMN2TSHRFEN1
SCHEMBL16333874 0.71 LMNA (0.48) LMNASMN1; SMN2KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3134087-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2020-03-18 EP disclosed
EP-3134087-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2020-03-18 EP disclosed
EP-3137469-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2019-10-09 EP disclosed
EP-3137469-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2019-10-09 EP disclosed
EP-3134405-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2019-08-28 EP disclosed
EP-3134405-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2019-08-28 EP disclosed
US-10077272-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2018-09-18 US disclosed
US-20180072750-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2018-03-15 US disclosed
US-20180072750-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2018-03-15 US disclosed
US-20180072750-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2018-03-15 US disclosed
US-20170037049-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2017-02-09 US disclosed
WO-2015166366-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-11-05 WO disclosed
WO-2015166366-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-11-05 WO disclosed
WO-2015166370-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-11-05 WO disclosed
WO-2015166370-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-11-05 WO disclosed
WO-2015162518-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-10-29 WO disclosed
WO-2015162518-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-10-29 WO disclosed
US-20150307522-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-10-29 US disclosed
US-20150307522-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-10-29 US disclosed
US-20150307522-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10077272-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, DRD4 ESR1 473/4885LMNA 4162/4885SMN1; SMN2 1446/4885
US-20180072750-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, DRD4 ESR1 473/4885LMNA 4162/4885SMN1; SMN2 1446/4885
US-20150307522-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, DRD4 ESR1 473/4885LMNA 4162/4885SMN1; SMN2 1446/4885
US-20170037049-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, DRD4 ESR1 513/4885LMNA 4291/4885SMN1; SMN2 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.